Sumitomo Pharma Oncology, Inc. has presented updated preliminary data from its ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy. The initial preliminary data was presented at the American Society of Hematology (ASH) Annual Meeting & Exposition 2022. Updated results were presented in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress, where it was shown that TP-3654 had been well-tolerated by patients and may prompt early cytokine changes that correlate with symptom response. The study showed spleen volume reduction and total symptom score improvement in relapsed/refractory MF patients who received TP-3654 monotherapy. Additionally, broad reductions in cytokines were observed after TP-3654 treatment, and higher cytokine reductions correlated with higher TSS improvement. Sumitomo Pharma Oncology is committed to advancing this program with additional clinical sites to improve outcomes for patients with myelofibrosis.
Keywords: Sumitomo Pharma Oncology, TP-3654, PIM1 kinase inhibitor, myelofibrosis, cytokine changes